Pharmaceutical

Santhera fully divests rare eye disease drug Raxone to Chiesi

Santhera Pharmaceuticals announced the complete worldwide divestment of Raxone (idebenone) to Chiesi Farmaceutici.

Jul 31, 2023 - 20:00
Santhera fully divests rare eye disease drug Raxone to Chiesi
Santhera Pharmaceuticals announced the complete worldwide divestment of Raxone (idebenone) to Chiesi Farmaceutici.
Read the original article

Tags:

Previous Article

Searchlight licenses Mithra’s menopause drug Donesta for Canadian market

Next Article

Multicyclic molecular wheels with polymer potential

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

AstraZeneca ends Phase IV Andexxa trial after positive results

AstraZeneca ends Phase IV Andexxa trial after positive ...

Jun 7, 2023

STAT+: Ventyx stock craters after lackluster mid-stage trial results for psoriasis drug

STAT+: Ventyx stock craters after lackluster mid-stage ...

Nov 7, 2023

Purdue receives clearance for opioid overdose injector for younger individuals

Purdue receives clearance for opioid overdose injector ...

Aug 9, 2024